Surgery, Ablation Lead to Similar Outcomes for Small Liver Tumors

Surgery, Ablation Lead to Similar Outcomes for Small Liver Tumors

(MedPage Today) -- Surgery and ablation for small liver tumors led to similar outcomes in a large study from Japan. Data from a randomized trial showed a 5-year overall survival (OS) of 74.6% with surgery and 70.4% with radiofrequency ablation...

Varian Launches IntelliBlate in Europe for Soft Tissue Tumor Treatment - Endovascular Today

July 18, 2025—Varian, a Siemens Healthineers company, recently announced the European launch of its next-generation IntelliBlate microwave ablation solution, which has received CE Mark approval for the minimally invasive treatment of soft tissue tumors. The company will introduce IntelliBlate to clinicians at CIRSE 2025. In the United States, IntelliBlate received FDA market clearance in 2024, noted Varian. With the addition of IntelliBlate, the…